The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.
Daniel Rabinowitz net worth and biography

Daniel Rabinowitz Biography and Net Worth

Insider of Natera
Daniel Rabinowitz is Secretary and Chief Legal Officer of Natera. Prior to joining Natera, he was a corporate partner at the law firm McDermott, Will & Emery, and, before that, was also a corporate lawyer at the law firm Davis Polk & Wardwell. He has worked in the United States and Europe advising domestic, foreign, public, and private companies on capital raisings, M&A, investment management and compliance with US federal and state securities law. He has studied genetics, biochemistry, and molecular biology at Harvard University Extension School and attended courses on the legal and ethical aspects of biotechnology at Harvard Law School. Mr. Rabinowitz completed his B.A. and LL.B. degrees at the University of the Witwatersrand, South Africa, graduating at the top of his law school class, and completed his LL.M. at New York University School of Law with both Rotary Foundation and Fulbright Scholarships. Admitted in New York only.

What is Daniel Rabinowitz's net worth?

The estimated net worth of Daniel Rabinowitz is at least $6.51 million as of January 23rd, 2023. Mr. Rabinowitz owns 148,853 shares of Natera stock worth more than $6,510,830 as of January 28th. This net worth evaluation does not reflect any other investments that Mr. Rabinowitz may own. Additionally, Mr. Rabinowitz receives a salary of $557,470.00 as Insider at Natera. Learn More about Daniel Rabinowitz's net worth.

How old is Daniel Rabinowitz?

Mr. Rabinowitz is currently 54 years old. There are 4 older executives and no younger executives at Natera. The oldest executive at Natera is Mr. Robert A. Schueren, Chief Operating Officer, who is 61 years old. Learn More on Daniel Rabinowitz's age.

What is Daniel Rabinowitz's salary?

As the Insider of Natera, Inc., Mr. Rabinowitz earns $557,470.00 per year. There are 3 executives that earn more than Mr. Rabinowitz. The highest earning executive at Natera is Mr. Steven Leonard Chapman, CEO, Pres & Director, who commands a salary of $925,590.00 per year. Learn More on Daniel Rabinowitz's salary.

How do I contact Daniel Rabinowitz?

The corporate mailing address for Mr. Rabinowitz and other Natera executives is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. Natera can also be reached via phone at (650) 249-9090 and via email at [email protected] Learn More on Daniel Rabinowitz's contact information.

Has Daniel Rabinowitz been buying or selling shares of Natera?

During the past quarter, Daniel Rabinowitz has sold $99,203.72 in Natera stock. Most recently, Daniel Rabinowitz sold 2,387 shares of the business's stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $41.56, for a transaction totalling $99,203.72. Following the completion of the sale, the insider now directly owns 148,853 shares of the company's stock, valued at $6,186,330.68. Learn More on Daniel Rabinowitz's trading history.

Who are Natera's active insiders?

Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), James Healy (Director), Gail Marcus (Director), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.

Are insiders buying or selling shares of Natera?

During the last twelve months, Natera insiders bought shares 2 times. They purchased a total of 372,820 shares worth more than $11,323,786.80. During the last twelve months, insiders at the medical research company sold shares 60 times. They sold a total of 96,087 shares worth more than $3,913,739.28. The most recent insider tranaction occured on January, 23rd when insider Daniel Rabinowitz sold 2,387 shares worth more than $99,203.72. Insiders at Natera own 10.3% of the company. Learn More about insider trades at Natera.

Information on this page was last updated on 1/23/2023.

Daniel Rabinowitz Insider Trading History at Natera

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/23/2023Sell2,387$41.56$99,203.72148,853View SEC Filing Icon  
12/23/2022Sell476$42.30$20,134.80146,537View SEC Filing Icon  
9/28/2022Sell729$44.04$32,105.16145,827View SEC Filing Icon  
9/23/2022Sell481$45.30$21,789.30145,192View SEC Filing Icon  
7/22/2022Sell342$46.26$15,820.92144,780View SEC Filing Icon  
6/28/2022Sell689$39.02$26,884.78144,478View SEC Filing Icon  
6/23/2022Sell446$35.76$15,948.96143,804View SEC Filing Icon  
4/22/2022Sell325$36.14$11,745.50143,358View SEC Filing Icon  
3/10/2022Sell884$42.16$37,269.44View SEC Filing Icon  
12/10/2021Sell899$91.33$82,105.67View SEC Filing Icon  
12/7/2021Sell3,151$91.99$289,860.49View SEC Filing Icon  
9/23/2021Sell446$125.67$56,048.82View SEC Filing Icon  
6/23/2021Sell449$115.18$51,715.8249,119View SEC Filing Icon  
6/4/2021Sell3,140$97.51$306,181.4050,507View SEC Filing Icon  
See Full Table

Daniel Rabinowitz Buying and Selling Activity at Natera

This chart shows Daniel Rabinowitz's buying and selling at Natera by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Natera Company Overview

Natera logo
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Read More

Today's Range

Now: $43.74
Low: $41.89
High: $44.21

50 Day Range

MA: $39.96
Low: $35.29
High: $43.74

2 Week Range

Now: $43.74
Low: $26.10
High: $74.82

Volume

659,164 shs

Average Volume

1,300,920 shs

Market Capitalization

$4.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.